Search
Amylopectin
go.drugbank.com/drugs/DB14927ExperimentalAmylopectin is under investigation in clinical trial NCT01708694 (Role of Slowly Digesible Starch on Diabetes Risk Factors).
CX501
go.drugbank.com/drugs/DB05174InvestigationalCx501 is used to treat epidermolysis bullosa (EB), a rare genetic condition which can lead to contraction of the joints, fusion of fingers and toes, contraction of the mouth membranes and narrowing of … It is developed by Cellerix and is in phase I of clinical trials.
XL820
go.drugbank.com/drugs/DB05146Investigationala variety of human cancers. … XL820 exhibits dose-dependent growth inhibition in models of breast carcinoma, gliomas and leukemia.
OT-551
go.drugbank.com/drugs/DB05650InvestigationalOT-551 is a novel small molecule that is topically dosed in an eye drop and has the unique ability to penetrate cell membranes and reach both the front and the back of the eye. … degeneration (AMD) by protecting against retina photoreceptor cell death and inhibiting angiogenesis, the growth of small blood vessels leading to the wet-form of AMD.
LX201
go.drugbank.com/drugs/DB04943InvestigationalLX201 is a silicone matrix ocular implant that provides sustained release of cyclosporine A (CsA) locally to the eye over the course of one year. … LX201 is implanted subconjunctivally (beneath the transparent membrane covering the white of the eye) in a minimally invasive procedure.
AG-702
go.drugbank.com/drugs/DB05836ExperimentalThis drug is developed by antigenics for the treatment of genital herpes infection and is under phase I of clinical trial. … It is also known as HSPs, which are a group of proteins that are induced when a cell undergoes various types of environmental stresses like heat, cold and oxygen deprivation.
Ertiprotafib
go.drugbank.com/drugs/DB06521ExperimentalErtiprotafib belongs to a novel class of insulin sensitizers developed for treatment of type 2 diabetes. … In insulin-resistant rodent models, ertiprotafib and a close analog lowered both fasting blood glucose and insulin levels and improved glycemic excursion during an oral glucose tolerance test.
Rebaudioside A
go.drugbank.com/drugs/DB15136InvestigationalRebaudioside A is under investigation in clinical trial NCT03510624 (Acute Effect of Rebaudioside A on Glucose Excursion During an Oral Glucose Tolerance Test in Type 2 Diabetes Mellitus).
Narlaprevir
go.drugbank.com/drugs/DB14760InvestigationalCategories: Antivirals for treatment of HCV infectionsHarmaline
go.drugbank.com/drugs/DB13875ExperimentalCategories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome